Hill August 1, 2023
The Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA) on Tuesday laid out steps they are taking to mitigate the ongoing shortage of prescription stimulants like Adderall.
Prescription stimulants, which are commonly used to treat attention-deficit/hyperactivity disorder (ADHD) and narcolepsy, have been in short supply since last fall, after a major drug maker encountered manufacturing delays.
While the delays have since been resolved, FDA Commissioner Robert Califf and DEA Administrator Anne Milgram noted in a letter to the American public Tuesday that the impacts have lingered and have been exacerbated by a rise in the use of prescription stimulants during the COVID-19 pandemic.
Califf and Milgram said their agencies are calling on drug manufacturers to increase production of...
Today's Sponsors
Today's Sponsor